Engineering transgene expression to respond specifically to intracellular cues holds transformative potential for monitoring cell states and modulating cellular functions. Here we introduce TRADER (Target-induced Transgene Activators via Reprogramming of dCas6-barnase Degrader), a versatile and modular platform that en...
Natural killer cell engagers (NKCEs) are promising immunotherapeutic agents for cancer treatment. However, their efficacy against solid tumors is severely limited by immune evasion mechanisms (mediated by the sialic acid-Siglec axis and PD-1/PD-L1 pathway), along with poor pharmacokinetics and off-target effects. Harne...
Wen-Jia Shi, Chao-Qiang Li, Wen-Rong Lai et al.· Journal of the American Chem...· 0 citations
Targeting mutant KRAS represents a critical yet unmet therapeutic challenge across multiple malignancies, as the structural diversity of oncogenic variants and absence of druggable pockets have impeded the development of effective small-molecule inhibitors. Here, we report an integrated RNA degrader system constructe...
Ying-Fu Li, Qing Huang, Pin-Ru Chen et al.· ACS Pharmacology & Trans...· 0 citations
Yarrowia lipolytica is a promising industrial host, yet its metabolic engineering potential remains limited by insufficient genetic tools. Here, we engineered a synthetic Transcription Activation Toolkit (TAT) based on LacI-VPRH, a chimeric protein fusing the prokaryotic DNA-binding domain LacI with the eukaryotic acti...
Yun-He Li, Wen-Ping Wei, Ping Zhang et al.· Journal of Agricultural and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
